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Abstract
Increased attention to timely diagnosis motivated us to study 5483 patients diagnosed with multiple myeloma using Medicare
claims linked to tumor registries in the Surveillance, Epidemiology and End Results programme. We calculated the time
between initial visits for anemia or back pain and for myeloma diagnosis, and used logistic regression to predict the likelihood
of diagnostic delay, and also the likelihood of renal or skeletal complications. The median time between sign or symptom and
myeloma diagnosis was 99 days. Patients with anemia, back pain and comorbidities were more likely to experience diagnostic
delay (OR 1.6, 95% CI 1.3–2.0). Diagnosis while hospitalised (OR 2.5, 95% CI 2.2–2.9) and chemotherapy treatment within
6 months of diagnosis (OR 1.4, 95% CI 1.2–1.6) significantly predicted complications; diagnostic delay did not (OR 0.9,
95% CI 0.8–1.1). Our data suggest that complications are more strongly associated with health status and myeloma severity
than with diagnostic delays.
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Introduction
Stakeholders in both the United States [1] and the
United Kingdom [2] have identified timeliness of
patient care as a high priority for quality improve-
ment efforts. One aspect of timeliness of care is the
interval between recognition of a sign or symptom
and a definitive diagnosis by a health care provider.
Rapid diagnoses may result in favorable patient
outcomes, including fewer complications and re-
duced mortality, as well as greater satisfaction with
care and a better perceived quality of life [3].
Concerns over delayed referral and diagnosis are
especially relevant for patients with cancer because of
an increased likelihood of disease-free survival when
tumors are detected at earlier stages [4–11]. In the
year 2000, the United Kingdom Department of
Health launched the Cancer Referral Guidelines,
which set a 2-week target for patients with suspected
cancers to be seen by an appropriate consultant [12].
To date, mixed results from this initiative have been
reported [13–16].
Barriers to timely cancer detection may be
categorised as those related to practitioners, patients
and health care systems [17]. Health service
researchers have studied predictors and adverse
outcomes associated with delays in diagnosis and
treatment of cancer, but the majority of these studies
have focussed on solid tumors, notably breast cancer
[18–22].
Analysis of results from the ‘1999–2000 National
Survey of NHS Patients – Cancer’ reveals that delays
in diagnoses vary for six tumor types studied: while
gender, age, socioeconomic status and race/ethnicity
Correspondence: Craig C. Earle, MD, Institute for Clinical Evaluative Sciences, Sunnybrook Health Sciences Centre, 2075 Bayview Avenue, Room G-106,
Toronto ON, M4N 3M5, Canada. Tel: þ1-416-480-4297. Fax: þ1-416-480-6048. E-mail: craig.earle@ices.on.ca
Leukemia & Lymphoma, March 2009; 50(3): 392–400

























































are all significant predictors of delay, the effects of
these factors are not uniform across tumors [23–25].
In a review of diagnostic delays reported in multiple
countries, we identified no variables consistently
associated with delays [26]. Further, we found no
empirical studies that examined diagnostic delays in
multiple myeloma.
Many patients with myeloma develop renal dys-
function and skeletal complications, such as fracture
or spinal cord compression, which decrease quality of
life and increase mortality [27]. These adverse
outcomes may be related to variations in the time
required to obtain myeloma diagnoses. For example,
data from 92 patients in a myeloma clinic were
analysed for the frequency of relapse and death based
on delayed presentation [28]. Forty-four percent of
patients with a delay in diagnosis exceeding 6 months
had relapsed or died at the end of the study period,
compared with 21% in the group of patients with
shorter delays (p5 0.05). These delays may occur
because of non-specific presenting symptoms. A
retrospective review of 1027 cases of myeloma
diagnosed between 1985 and 1998 at the Mayo
Clinic identified a high prevalence of anemia and
bone pain as an initial sign and symptom [29]. These
conditions were also observed in a Dutch registry of
127 patients diagnosed with myeloma between 1991
and 1993, 37% of whom did not have myeloma
according to the initial differential diagnosis [30].
From these retrospective, single-site studies of
patients with myeloma, we cannot clearly identify
consistent predictors of delay, nor can we link delays
in diagnosis and treatment to the likelihood of
complications. Moreover, very few studies address
the issue of delay in patients with hematological
malignancies. The present report attempts to bridge
these gaps by identifying the predictors of diagnostic




We used the Surveillance, Epidemiology and End
Results (SEER) – Medicare data set to identify
patients diagnosed with multiple myeloma. Through
collaborations among the National Cancer Institute,
the Center for Medicare and Medicaid Services and
participating state and regional cancer registries, the
SEER-Medicare data set combines cancer registry
information with complete claims data for adults age
65 and above enrolled in traditional Medicare Parts
A and B [31]. The analysis sample contained patients
diagnosed with multiple myeloma between 1
February 1992 and 31 December 2002. The 16
registries in this dataset cover a representative sample
of 26% of the population of the United States. Prior
studies have documented that the participating
tumor registries captured *97% of incident cases
reported by hospitals [32]. The data set is particularly
rich in racial and ethnic minority populations
[33,34]. Our study protocol was granted exempt
review from the Dana-Farber Cancer Institute
Institutional Review Board. The principal investiga-
tor executed a signed data-use agreement with the
SEER-Medicare coordinating center.
Study sample
We used the cancer registry data to identify patients
with multiple myeloma diagnoses, confirmed via
pathologic, radiologic or laboratory findings. Patients
with multiple cancers were eligible if multiple
myeloma was the first cancer diagnosed. The SEER
cancer diagnosis date (henceforth defined as diag-
nosis date) had to be on, or after, the patient’s date of
Medicare enrollment and patients had to survive six
or more months following diagnosis. To measure
health care utilisation for signs or symptoms, patients
had to be continuously enrolled in both Part A and
Part B Medicare in the year prior to their diagnosis.
Following a definitive diagnosis, patients had to
survive for at least 6 months so we could examine use
of chemotherapy, incidence of complications and
performance of diagnostic studies. We identified
8735 patients in the participating registries who were
diagnosed with multiple myeloma between 1992 and
2002 and who met eligibility criteria.
Of these, we excluded 2952 patients based on the
following: diagnosis at autopsy, eligible for Medicare
because of end-stage renal disease or disability and
participation in Medicare health maintenance orga-
nisations during the study period. Forty patients with
a claim for amyloidosis made prior to their myeloma
diagnosis were excluded, and 260 patients were not
included because no physician, outpatient or hospital
claims specifying a myeloma diagnosis were avail-
able. The final analysis sample consisted of 5483
patients. We defined the study period for an
individual patient as starting the year prior to
diagnosis date, and ending up to 6 months following
the diagnosis date.
Study variables
Patient characteristics. The Patient Entitlement and
Diagnosis Summary File was used to measure patient
characteristics, including age, gender, race/ethnicity,
geographic region of residence, and residence in an
urban versus rural area. Medicare inpatient (MED-
PAR), outpatient (OUTSAF) and physician (NCH)
























































files were used to construct a modified Charlson
comorbidity score for all patients by reviewing claims
for the year prior to the SEER diagnosis date [35].
We measured all physician visits and hospitalisations
for patients by summing the number of claims filed
during the year prior to diagnosis.
Signs and symptoms, diagnostic and therapeutic
procedures. Based upon our review of the literature
[27–30], and in consultation with clinicians treating
patients with myeloma, we matched signs and
symptoms frequently associated with myeloma –
determined to be anemia, packed red blood cell
(PRBC) transfusion, and back pain – to diagnoses
and procedures from the claims data using Interna-
tional Classification of Diseases, 9th edition (ICD-9)
and current procedural terminology (CPT) codes.
We created dichotomous variables to identify the
presence or absence of claims for these signs and
symptoms during the 6 months preceding the SEER
diagnosis date. We also considered certain proce-
dures to be proxies for the diagnosis of multiple
myeloma, and identified them using CPT and ICD-9
procedure codes. These procedures included urine
or serum protein electrophoresis (PEP), bone mar-
row biopsy and bone scan or skeletal survey. We also
identified bisphosphonate or chemotherapy infusions
following diagnosis. A table with all of the codes that
were used to create these variables is available in
Appendix.
Myeloma diagnosis, delay and complications. Because of
reporting lags, SEER diagnosis dates have a window
of +30 days for accuracy [36]; all calculations of the
time between diagnosis dates and dates of signs,
symptoms or diagnostic procedures were thus
adjusted for these lags; the final results were un-
changed when unadjusted windows were used. We
measured the number of days between the first claim
of a sign or symptom of myeloma and the diagnosis
date (with the above-mentioned adjustment).
Literature review and consultation with myeloma
clinicians led us to identify ICD-9 and CPT codes
that reflect complications occurring up to 6 months
following the diagnosis date; in this analysis we focus
on renal failure and skeletal complications (see
Appendix). Patients were excluded from the analysis
of complications if they had claims for either of these
conditions in the year prior to the diagnosis date.
Data analysis
Examination of delays. For the 3831 patients who had
a claim for a myeloma-related sign or symptom
preceding myeloma diagnosis, we calculated the
number of days between the diagnosis date and the
initial claim for a sign or symptom. We used an
ordered logistic regression model to estimate the
likelihood of an increasing gap between the initial
sign or symptom date and the diagnosis date based
on the quartile distribution of diagnosis times for the
sample. Patient demographics, comorbidities, health
care utilisation in the prior year and initial source of
diagnosis were considered for the model, and
variables were retained using the ‘Purposeful Selec-
tion’ algorithm [37]. Parameter estimates changed
for the presence of a sign or symptom when
comorbidity values were entered into the model.
Thus, an interaction term was added to reflect the
presence of one or more comorbidities, and the
presence of both anemia and back pain (prior to
diagnosis). The parameter estimates, variance and
covariance were used to calculate the effect sizes for
patients with at least one comorbidity, plus anemia
and back pain, versus patients with one comorbidity
and either anemia or back pain [38].
Predictors of complications. After excluding patients
with a renal or skeletal complication recorded in
claims prior to the diagnosis date, 5406 patients were
available for analysis. A logistic regression model
predicted the likelihood of a renal or skeletal
complication subsequent to the diagnosis date. The
main independent variable of interest was delay
(defined as exceeding the sample’s median value)
between sign or symptom and diagnosis. Additional
covariates included the demographic variables pre-
viously mentioned, as well as diagnostic or therapeu-
tic procedures performed. Sensitivity analyses were
performed to examine the effect of a three-category
variable of diagnostic delay (delay, no delay, missing
sign or symptom information). We also estimated the
likelihood of complication when diagnostic delays
exceeded the tenth percentile of the sample distribu-
tion. We also estimated a model that includes an
interaction of comorbidity and diagnostic delay.
We used SAS 9.1.3 (Cary, NC) for all analyses.
Coefficients obtained from logistic regression models
were expressed as odds ratios (ORs), with corre-
sponding 95% confidence intervals (CIs).
Results
Patient characteristics
Of the 5483 patients who met study criteria (full
sample), 3831 (70%) had a claim for a sign or
symptom prior to the diagnosis of multiple myeloma.
Table I compares the patient characteristics by three
subsamples: (a) patients who had no claim for sign or
symptom prior to diagnosis (no claim); (b) patients
who had a sign or symptom, but were diagnosed
























































sooner than the median period of time for the sample
(no delay), and (c) patients who had a sign or
symptom, and were diagnosed later than the median
period of time for the sample (delay). Significant
differences were observed for age, race, gender,
comorbidity, geographic region and prior physician
visits. Patients who experienced delay were an
average of 1 year older. When comparing the
distribution of race by sample, a larger proportion
of black patients (14.9%) experienced a diagnostic
delay than is observed in the other subsamples
(11.1% and 13.0%), and a similar pattern was
observed for women (58.0% in the delay sample,
48.3% and 49.1% in the no claims or no delay
sample, respectively). Significantly more patients in
the delay sample had two or more comorbidities, and
had more physician visits in the year prior to
diagnosis.
The frequency of claims for a sign or symptom
prior to myeloma diagnosis was high; Figure 1 shows
frequencies of claims for anemia or PRBC transfu-
sions (50%), back pain (39%) and for both anemia/
transfusion and back pain (19%) prior to myeloma
diagnosis. Roughly half of the patients had a claim for
PEP of the urine or serum, 37% had a bone marrow
biopsy and 42% had either a bone scan or skeletal
survey. Because the ICD-9 and CPT codes changed
during the study period, we were unable to clearly
distinguish between bone scans and skeletal surveys.
Less than a quarter of study patients received both
PEP and bone marrow biopsy, and only 17%
received all three diagnostic tests (PEP, bone marrow
biopsy and radiographic evaluation).
Table I. Characteristics of study patients, by analytic sample (n¼ 5483).






Age in years, mean+STD 75.9+6.4 75.7+ 6.4 76.9+ 6.6 50.0001
Race, n (%)
White 1415 (85.7) 1588 (83.0) 1542 (80.4)
Black 184 (11.1) 248 (13.0) 286 (14.9)
Other 53 (3.2) 77 (4.0) 90 (4.7) 50.01
Gender, n (%)
Male 854 (51.7) 973 (50.9) 805 (42.0)
Female 798 (48.3) 940 (49.1) 1113 (58.0) 50.0001
Urban resident, n (%) 1508 (91.3) 1738 (90.1) 1725 (90.0) 0.36
Charlson score, n (%)
0 687 (41.6) 845 (44.2) 679 (35.4)
1 331 (20.0) 350 (18.3) 494 (25.8)
2þ 147 (8.9) 190 (9.9) 368 (19.2)
No claims 487 (29.5) 528 (27.6) 377 (19.7) 50.0001
Region of residence, n (%)
Northeast 308 (18.6) 347 (18.1) 315 (16.4)
South 180 (10.9) 230 (12.0) 216 (11.3)
Midwest 407 (24.6) 506 (26.5) 549 (28.6)
West 757 (45.8) 830 (43.4) 838 (43.7) 0.10
Physician visits in year
prior to myeloma
diagnosis, median, IQR
7, 4–13 9, 5–13 13, 8–19 50.0001
Note: Percentages may not total 100 percent due to rounding. STD, standard deviation; IQR, interquartile range.
Figure 1. Frequency of pre-diagnosis signs, symptoms and
procedures (n¼ 5483). The majority of study patients experienced
anemia or had a transfusion of PRBCs prior to myeloma diagnosis.
Less than 25% of patients had PEP and bone marrow biopsy prior
to diagnosis.
























































Frequency and predictors of diagnostic delay
For the 3831 patients in the delay sample, 137 days
(mean, SD 120, range 1–365) elapsed between the
first claim for a myeloma sign or symptom and
myeloma diagnosis; the median was 99 days (inter-
quartile range¼ 27–252). In more than 66% of the
delay sample, the difference between the date of
claim for a sign or symptom and myeloma diagnosis
exceeded 30 days; subsequent analyses defined delay
as exceeding the median number of days between
sign or symptom and myeloma diagnosis. Table II
shows the results from the ordered logistic regression
model for estimating the likelihood of delay between
sign or symptom and diagnosis, based on the quartile
distribution. The presence of at least one comorbid-
ity, in addition to both anemia/PRBC and back pain
prior to myeloma diagnosis, was the strongest
predictor of diagnostic delay (OR 1.6, 95% CI 1.3–
2.0). However, the likelihood of delay was also high
when comorbidity was present with only anemia or
back pain (OR 1.4, 95% CI 1.2–1.6). Increased
physician (OR 1.1, 95% CI 1.0–1.1) or hospital (OR
1.1, 95% CI 1.0–1.1) visits in the year preceding
diagnosis increased the likelihood for delay. Other
significant predictors of delay included the year of
diagnosis, increasing age at the time of diagnosis, and
non-white race/ethnicity. Males (OR 0.8, 95% CI
0.7–0.8) and patients initially diagnosed during an
inpatient stay (OR 0.7, 95% CI 0.6–0.8) were
significantly less likely to experience delay.
Predictors of post-diagnosis complications
After excluding 77 patients who had claims for renal
or skeletal complications prior to myeloma diagnosis,
5406 patients were used to examine frequency and
predictors of complications following myeloma diag-
nosis. Over a third of patients experienced at least
one skeletal or renal complication (n¼ 1851); of
these, 1160 patients had cord compression or
fracture, and 796 experienced renal failure after
diagnosis (105 patients experienced both). The
results of the logistic regression model are shown in
Table III. Patients initially diagnosed during an
inpatient stay were more than more than twice as
likely to experience a complication as those who
were diagnosed as outpatients (95% CI 2.2–2.9).
Additional significant predictors of complications
included systemic chemotherapy within 6 months
after diagnosis, and more inpatient stays in the year
preceding diagnosis. Patients who had undergone
bone marrow biopsy and PEP prior to diagnosis were
significantly less likely to experience a complication
(OR 0.6, 95% CI 0.5–0.6) than those who did not
receive these diagnostic studies. We did not detect a
significant effect of delay between sign or symptom
and diagnosis on the likelihood of complications (OR
0.9, 95% CI 0.8–1.1). Our results did not change
Table II. Ordered logistic regression model predicting that the








Year of diagnosis 1.03 1.01–1.06





Non-white race/ethnicity 1.19 1.02–1.39
No. of physician visits in past year 1.05 1.05–1.06
No. of inpatient stays in past year 1.07 1.02–1.13
Comorbidity: 1 present
Anemia/PRBCþ back pain 1.58 1.25–2.00
No anemia/PRBCþ back pain 1.37 1.18–1.59
Diagnosed during inpatient stay 0.73 0.64–0.84
PRBC, packed red blood cell transfusion. Age at diagnosis
measured for increasing year of age; Geographic regions were
compared to West; non-white race/ethnicity was compared with
white.
Table III. Logistic regression model predicting renal or skeletal







Year of diagnosis 1.01 0.98–1.03





Non-white race/ethnicity 0.94 0.80–1.10
No. of physician visits in past year 1.01 1.00–1.01
No. of inpatient stays in past year 1.06 1.01–1.12
Comorbidity: 1 present 1.09 0.95–1.24
Diagnosed during inpatient stay 2.53 2.22–2.88
Bisphosphonate within 6 months
after diagnosis
1.08 0.93–1.25
Chemotherapy within 6 months
after diagnosis
1.40 1.24–1.59
BMBþPEP prior to diagnosis 0.55 0.47–0.64
Delay between sign or symptom
and diagnosis
0.91 0.80–1.03
BMB, bone marrow biopsy; PEP, serum or urine protein
electrophoresis. Age at diagnosis measured for increasing year of
age; Geographic regions were compared to West; non-white race/
ethnicity was compared with white. Delay defined as exceeding
sample median of time between myeloma diagnosis and sign or
symptom.
























































when considering a three-category variable of delay
(no claim, delay and no delay), when we changed the
measure of delay to meet or exceed the tenth
percentile, or when an interaction term between
comorbidity and delay was included (results not
shown).
Discussion
We found that Medicare enrollees in 13 regions of the
United States experienced substantial variations in
the timeliness of diagnostic work up for multiple
myeloma. For example, for patients who visit a
physician or hospital with signs or symptoms of
myeloma, the time between the initial visit and
definitive diagnosis ranges from 1 to 365 days, with
mean of 137. Half of our study patients were
diagnosed 99 or more days after the first visit. Male
patients and patients diagnosed during an inpatient
stay were significantly less likely to experience a delay
of more than 99 days; however, non-white patients,
patients with more physician visits and hospitalisa-
tions, and patients with comorbidities, were more
likely to experience a delay as defined by our
methods.
Nearly 20% of patients with any comorbidity, in
addition to anemia and back pain, had a significantly
greater likelihood of experiencing a delay in diagnosis
of myeloma. Curiously, despite the presence of a sign
or symptom often associated with myeloma, the
diagnostic process appears to be more difficult when
patients experience multiple medical problems,
whether measured by actual number of comorbidities
or heavy service utilisation. This may be because
primary care providers are focussed on acute
problems, and overlook signs and symptoms of
myeloma. The lower likelihood of diagnostic delay
for hospitalised patients may occur because multiple
specialist consultants and more advanced diagnostic
equipment are readily available in the inpatient
setting, thus facilitating the completion and inter-
pretation of diagnostic tests.
In our cohort, race was significantly associated
with the timeliness of diagnostic workup that patients
with myeloma received, affirming previous findings
from other cancer patient populations [25]. The
reasons for this are not clear and warrant further
investigation; perhaps patients differ in their report-
ing of symptoms or may seek care in different ways
based on race. In our analyses, females were more
likely to experience diagnostic delay. However,
because diagnostic delay is most frequently studied
in gender-specific tumors, very little data are avail-
able on gender differences. One recent report that
included colorectal and lung cancers found longer
delays for women, but these differences were not
statistically significant [25]. However our finding of
increased diagnostic delays for females has also been
reported in tuberculosis [39] and cardiovascular
disease [40–42]. And despite more frequent diag-
nostic delays for women, research findings have
shown increased distress from delays for women
compared with men [43]. When comparing the
effects of race and of gender on diagnostic delay for
myeloma, the gender divide appears greater than the
racial divide. Our data suggest it is difficult to sort the
variance in diagnostic delay into discrete categories,
such as patients, providers and health systems.
Further study of interactions among these domains
is warranted. Interestingly, despite the significant
effect of race and gender on diagnostic delay, these
factors were not implicated in the likelihood of
complications.
We found no evidence for a direct relationship
between delayed diagnosis and skeletal or renal
complications. Rather, the primary predictors of
complications were diagnoses made in the inpatient
setting and administration of chemotherapy within 6
months of diagnosis; these factors may reflect poorer
overall health status and higher severity of myeloma.
When bone marrow biopsy and PEP were both
performed close to the diagnosis date, the likelihood
of complications was significantly reduced; however,
less than 25% of patients had both procedures
performed prior to diagnosis, and even fewer
received additional radiographic evaluation for frac-
ture. Thus, while it may often be assumed that
diagnostic delays may pose harm to patients with
cancer in general, our empirical findings do not show
this to be the case for older adults with myeloma.
Alternately, delays between diagnosis and treatment,
or abnormal test results and treatment, may have
significant associations with outcomes, and warrant
further study.
Our finding of infrequent use of readily available
diagnostic tests for myeloma is provocative given
previous research findings that providers consider
myeloma infrequently in the differential diagnosis of
common signs and symptoms such as anemia and
back pain [30]. A recent survey of primary care
providers suggests that most are not familiar with
PEP as a diagnostic test for myeloma [44]. Adoption
of diagnostic guidelines [45] may enable providers to
identify aggressive myeloma and initiate therapy
earlier, which may have heightened significance as
newer myeloma therapies have resulted in promising
response rates [46,47].
Our data have limitations. First, they reflect a
limited availability of data on the patient experience
and actual clinical encounters. Second, we were not
able to analyse total nor monoclonal protein levels,
and clinicians may defer formal work up in patients
























































with low levels, which would reflect smoldering
myeloma [47]. Third, our data do not include a
measure of corticosteroid administration, which is
often used to initially stabilise myeloma and may
affect skeletal complications. Fourth, our study is
restricted to traditional Medicare enrollees who did
not participate in managed care plans, which, despite
including a large number of patients with myeloma,
limits the generalisability of our findings. Replication
of our analyses in populations where provider
availability may be improved, such as health main-
tenance organisations or in the Veterans Health
Administration, would help determine if provider
factors are a contributing factor in diagnostic delay.
Fifth, while the majority of patients with myeloma are
diagnosed in older age, the benefits of newer agents
have been more clearly demonstrated in younger
patients who are eligible for transplantation [48].
Finally, no consensus exists for determining a
clinically significant period of time between myeloma
diagnosis and evaluation for a related sign or
symptom. Thus, it is not yet clear how delay should
be measured for analysis, and our use of the median
time between sign or symptom for patients in the
reported analyses may not be ideal; on the other
hand, we estimated models using the mean, quartile
categories, the tenth percentile, and a continuous
measure, and obtained similar results.
In summary, while we did not see evidence of a
relationship between diagnostic delay and complica-
tions for patients with multiple myeloma, we did
observe significant differences in timeliness of care
for patients by gender, race, and clinical complexity.
Complications were, in general, most strongly
associated with myeloma severity and overall health.
Our data also suggest that reductions in complica-
tions might be achieved by performing bone marrow
biopsy and PEP during the initial diagnostic workup,
perhaps because the information obtained can be
used to individualise treatments. Finally, the pre-
sence of multiple comorbidities may act to mask even
signs and symptoms of myeloma, an unfortunate
finding, as those patients with comorbidities are the
ones most likely to need rapid diagnosis and
treatment.
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